Nuvation Bio (US:NUVB) Seeking Alpha·2026-01-14 03:16Company Overview - Nuvation Bio is a commercial stage biotechnology company with several products in late-stage development [2] - The company’s lead commercial asset, IBTROZI (taletrectinib), is a next-generation ROS1 inhibitor approved for treating ROS1-positive non-small cell lung cancer [2] Product Pipeline - Safusidenib is a potentially best-in-class mutant IDH1 inhibitor currently in a pivotal study for treating both high-grade and low-grade gliomas [3] - NUV-868 is a BD2-selective BET inhibitor that has completed Phase I studies [3] - The company is also developing a novel drug-drug conjugate preclinical program aimed at providing targeted therapy to cancers [3] Financial Position - Nuvation Bio has a cash balance of approximately $589 million following a recent deal with Eisai [4] - The company anticipates a path to profitability without the need for further funding [4] - IBTROZI is being commercialized in partnership with Eisai, Innovent, and Nippon Kayaku [4]